Suppr超能文献

严重 COVID-19 的脑部 MRI 表现:一项回顾性观察研究。

Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study.

机构信息

From the Hôpitaux Universitaires de Strasbourg, Service d'Imagerie 2, Hôpital de Hautepierre, Strasbourg, France (S.K.).

Author affiliations: Hôpitaux Universitaires de Strasbourg, Service d’Imagerie 2, Hôpital de Hautepierre, Strasbourg, France (S.K., F.L., S.B., F.D.A., T.W.); Engineering Science, Computer Science and Imaging Laboratory (ICube), Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg-CNRS, Strasbourg, France (S.K.); Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France (J.d.S., C. Boulay, V.M., M. Anheim); CHU Rennes, Department of Neuroradiology, Rennes, France (J.C.F., B.C.N.); Service de Maladies Infectieuses et Réanimation Médicale, CHU Rennes, France (A.M.); Hôpitaux Universitaires de Strasbourg, Service d’Anesthésie-Réanimation, Nouvel Hôpital Civil, Strasbourg, France (O.C., P.M.M.); Service de Neuroradiologie, CHU Toulouse, Toulouse, France (F. Bonneville., G.A.); Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France (G.M.B.); Department of Neurology, Toulouse University Hospital, Toulouse, France (M.R.); Department of Anesthesia and Critical Care, Toulouse University Hospital University Toulouse 3-Paul Sabatier, Toulouse, France (T.G., L.D.); Service de Neuroradiologie Diagnostique et Interventionnelle, Centre Hospitalier Universitaire des Alpes, Grenoble, France (S.G., A. Krainik); Nephrology and Transplantation Department, Hôpitaux Universitaires de Strasbourg, Inserm UMR S1109, LabEx Transplantex, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France (S. Caillard); EA CHIMERE 7516, Université de Picardie Jules Verne, Amiens, France; Service de NeuroRadiologie, Pôle Imagerie Médicale, Centre Hospitalo-Universitaire d’Amiens, Amiens, France (J.M.C., A.H.); Service de Neuro Radiologie, Pôle Imagerie Médicale, Centre Hospitalo-Universitaire d’Amiens, Amiens, France (S.M.); Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Strasbourg, France (J.H., F.M.); Immuno-Rhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d’Immunologie et d’Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France (J.H.); Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Hautepierre, Strasbourg, France (M.S., F.S.); Service de Maladies Infectieuses, NHC, CHU de Strasbourg, Strasbourg, France (N.L., Y.H.); Service de Radiologie, CHU de Saint-Etienne, Saint-Etienne, France (C. Boutet); Service de Réanimation, CH de Roanne, Roanne, France (X.F.); University Hospital of Limoges, Neuroradiology Department, Limoges, France (G.F., S.S.); Radiology Department, Hôpital Privé d’Antony, Antony, France (I.d.B., G. Bornet); Service d’Imagerie Pédiatrique et Fœtale, Hôpital Femme Mère Enfant, HCL, Lyon, France (A. Lacalm); Service de Neuroradiologie, Hôpitaux Civils de Colmar, Colmar, France (H.O., F. Bolognini, J.M.); INSERM U1266, Service d’Imagerie Morphologique et Fonctionnelle, GHU Psychiatrie et Neurosciences, Site Sainte-Anne, Paris, France (G.H., J. Benzakoun, C.O., G. Boulouis, M.E.G., B.K.); Service de Neuroradiologie, CHU Henri Mondor, Créteil, France (B.B., I.M.); Neuroradiology Unit, Department of Radiology, Assistance Publique–Hôpitaux de Paris (APHP), Bichat University Hospital, Paris, France (M.C.H.F., A.G.); Department of Radiology, Assistance Publique–Hôpitaux de Paris (APHP), Denis Diderot University and Medical School, Bichat University Hospital, Paris, France (A. Khalil); CHIC Unisanté, Hôpital Marie Madeleine, Forbach, France (L.J., P.N., Y.T.M.); Service de Radiologie 1, GHR Mulhouse Sud Alsace, Hôpital Mère Enfants, Mulhouse, France (C.H., P.F., N.S.); Service de Neurologie, Centre Hospitalier de Haguenau, Haguenau, France (S. Carré, C.L.); Service de Radiologie, Centre Hospitalier de Haguenau, Haguenau, France (M. Alleg); Service de Neuroradiologie, Hôpital Central, CHU de Nancy, Nancy, France (E.S., R.A., F.Z.); Department of Neuroradiology, University Hospital of Dijon, Hôpital François Mitterrand, Dijon, France (P.O.C., F.R., P.T.); Department of Diagnostic and Interventional Neuroradiology, University Hospital, Nantes, France (H.D.); Neuroradiology Department, CHU de Bordeaux, Bordeaux, France (J. Berge); Service de Neuroradiologie, CHU de Lille, Lille, France (A. Kazémi); Assistance Publique Hôpitaux de Paris, Service de Neuroradiologie, Hôpital Pitié-Salpêtrière, Paris, France Sorbonne Université, Univ Paris 06, UMR S 1127, CNRS UMR 7225, ICM, F-75013, Paris, France (N.P.); Neuroradiology Department, Fondation A. Rothschild Hospital, Paris, France (A. Lecler); Hôpitaux Universitaires de Strasbourg, UCIEC, Pôle d’Imagerie, Strasbourg, France (P.E.Z., M.M.); Observatoire Français de la Sclérose en Plaques, Lyon, France (J.C.B.); Hôpitaux Universitaires de Strasbourg, Laboratoire de Virologie Médicale, Strasbourg, France (S.F.K.); Radiology Department, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France (M.O.); INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France (F.M.); Department of Anaesthesia and Intensive Care, Lyon-Sud Hospital, Hospices Civils de Lyon, F-69495 Pierre Benite; University Claude Bernard Lyon 1, Lyon, France (J.S.D.); CHU de Strasbourg, Service de Santé Publique, GMRC, F-67091 Strasbourg, France (N.M.); Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France (M. Anheim); MRI Center, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France (F.C.); and Université Lyon 1, CREATIS-LRMN, CNRS/UMR/5220-INSERM U630, Villeurbanne, France (F.C.).

出版信息

Radiology. 2020 Nov;297(2):E242-E251. doi: 10.1148/radiol.2020202222. Epub 2020 Jun 16.

Abstract

Background Brain MRI parenchymal signal abnormalities have been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Purpose To describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe coronavirus disease 2019 (COVID-19) infection. Materials and Methods This was a retrospective study of patients evaluated from March 23, 2020, to April 27, 2020, at 16 hospitals. Inclusion criteria were () positive nasopharyngeal or lower respiratory tract reverse transcriptase polymerase chain reaction assays, () severe COVID-19 infection defined as a requirement for hospitalization and oxygen therapy, () neurologic manifestations, and () abnormal brain MRI findings. Exclusion criteria were patients with missing or noncontributory data regarding brain MRI or brain MRI showing ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event. Categorical data were compared using the Fisher exact test. Quantitative data were compared using the Student test or Wilcoxon test. < .05 represented a significant difference. Results Thirty men (81%) and seven women (19%) met the inclusion criteria, with a mean age of 61 years ± 12 (standard deviation) (age range, 8-78 years). The most common neurologic manifestations were alteration of consciousness (27 of 37, 73%), abnormal wakefulness when sedation was stopped (15 of 37, 41%), confusion (12 of 37, 32%), and agitation (seven of 37, 19%). The most frequent MRI findings were signal abnormalities located in the medial temporal lobe in 16 of 37 patients (43%; 95% confidence interval [CI]: 27%, 59%), nonconfluent multifocal white matter hyperintense lesions seen with fluid-attenuated inversion recovery and diffusion-weighted sequences with variable enhancement, with associated hemorrhagic lesions in 11 of 37 patients (30%; 95% CI: 15%, 45%), and extensive and isolated white matter microhemorrhages in nine of 37 patients (24%; 95% CI: 10%, 38%). A majority of patients (20 of 37, 54%) had intracerebral hemorrhagic lesions with a more severe clinical presentation and a higher admission rate in intensive care units (20 of 20 patients [100%] vs 12 of 17 patients without hemorrhage [71%], = .01) and development of the acute respiratory distress syndrome (20 of 20 patients [100%] vs 11 of 17 patients [65%], = .005). Only one patient had SARS-CoV-2 RNA in the cerebrospinal fluid. Conclusion Patients with severe coronavirus disease 2019 and without ischemic infarcts had a wide range of neurologic manifestations that were associated with abnormal brain MRI scans. Eight distinctive neuroradiologic patterns were described. © RSNA, 2020.

摘要

背景 脑 MRI 实质信号异常与严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)有关。目的 描述严重 2019 年冠状病毒病(COVID-19)感染患者的神经影像学表现(不包括缺血性梗死)。材料与方法 这是一项回顾性研究,纳入了 2020 年 3 月 23 日至 4 月 27 日在 16 家医院接受评估的患者。纳入标准为()鼻咽部或下呼吸道逆转录酶聚合酶链反应检测呈阳性,()需要住院治疗和氧疗的严重 COVID-19 感染,()神经系统表现,以及()异常脑 MRI 结果。排除标准为脑 MRI 缺少或不相关数据,或脑 MRI 显示缺血性梗死、脑静脉血栓形成或与当前事件无关的慢性病变。采用 Fisher 确切概率法比较分类数据。采用 Student 检验或 Wilcoxon 检验比较定量数据。<.05 表示有统计学差异。结果 37 例患者中 30 例男性(81%)和 7 例女性(19%)符合纳入标准,平均年龄为 61 岁±12(标准差)(年龄范围,8-78 岁)。最常见的神经系统表现为意识改变(27/37,73%)、镇静停止后觉醒异常(15/37,41%)、意识模糊(12/37,32%)和激越(7/37,19%)。最常见的 MRI 表现为 16 例患者(43%;95%置信区间[CI]:27%,59%)存在位于内侧颞叶的信号异常,37 例患者中(30%;95%CI:15%,45%)存在非融合性多灶性脑白质高信号病变,液体衰减反转恢复和弥散加权序列上有不同程度的增强,同时伴有 11 例患者(30%;95%CI:15%,45%)出血性病变,9 例患者(24%;95%CI:10%,38%)有广泛孤立性脑白质微出血。大多数患者(20/37,54%)存在颅内出血性病变,这些患者的临床表现更严重,入住重症监护病房的比例更高(20/20 例患者[100%]vs 12/17 例无出血患者[71%], =.01),急性呼吸窘迫综合征的发生率也更高(20/20 例患者[100%]vs 11/17 例患者[65%], =.005)。仅有 1 例患者的脑脊液中存在 SARS-CoV-2 RNA。结论 严重 COVID-19 且无缺血性梗死的患者有多种神经系统表现,这些表现与异常的脑 MRI 扫描有关。本文描述了 8 种不同的神经影像学表现模式。© 2020 RSNA。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c9/7301613/f4de417761a8/radiol.2020202222.fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验